

GUIDELINE FOR BK VIRUS SCREENING AND TREATMENT POST-TX

I. PURPOSE - To outline the evaluation and management of BK viremia post kidney transplant.

II. SETTING - Inpatient and Outpatient

III. DEFINITIONS

BK polyoma virus is the main cause of polyomavirus-associated nephropathy (BKVAN or PyVAN) after kidney transplantation and PyV-associated hemorrhagic cystitis in stem cell transplant (HCT). Both PyVAN and PyVHCT are rarely seen in non-kidney SOT. In addition, isolated cases of encephalitis, pneumonitis, retinitis, colitis, hemophagocytic syndrome and urothelial cancer have been described. BKV disease occurs almost exclusively in immunocompromised hosts but requires additional factors specific to patient and clinical setting to unfold its pathogenic impact.

Renal graft dysfunction and failure is the biggest risk of BK Viremia. Early identification and intervention reduces the risk of graft failure. Risk factors include donor factors such as recent viral exposure, female gender, HLA mismatches; recipient factors such as younger age, male gender, highly sensitized status; other factors such as ureteric stents, ATN, acute rejection treatment, steroids, lymphocyte depleting agents, re-transplant after graft loss due to PyVAN.

IV. POLICY

1. SCREENING AND DIAGNOSIS:

- a. Urine BK PCR: Urine BK PCR is not recommended as a screening test; not specific for disease
- b. Plasma BK PCR: recommended method for screening. Inter assay-variability exists, serial monitoring should be done using the same lab. Diagnostic titer > 1,000 copies/mL in 2 measurements within 3 weeks.
- c. Screen monthly x 9 months, then quarterly x 2 yr post-tx; then annually x 5 yr post-tx
- d. Screen whenever there is graft dysfunction, biopsy performed or after rejection treatment
- e. Urine cytology: the presence of “decoy cells” are markers of BK replication, not necessarily indicating nephropathy
- f. Renal biopsy: Gold standard for dx of BKN; Histology, + immunohistochemistry tests. Obtain if there is evidence of renal dysfunction; or if pts have increased risk of rejection with reduced IS, such as being highly sensitized, have DSA, or re-transplanted pts. Biopsy is not required if there are no risk factors for rejection and renal fx is at baseline.
- g. Scoring: Banff score for BKN
- h. If BK viral load above threshold detected with no renal dysfunction, confirm with repeat within 3 weeks; if increasing, proceed with reducing IS as described below.

2. TREATMENT:

- a. Reduce dose of anti-metabolite by 25-50%; continue same doses of CNI and prednisone (if on prednisone)
- b. Monitor viral load every 2 weeks using the same laboratory

- c. Monitor renal fx and Allosure closely
- d. If high viral load same or increased after 2 weeks, stop anti-metabolite
- e. If viral load same or increased after 4 weeks, reduce CNI dose to target lower levels (4-6 for tac and 50-100 for CsA)
- f. Other options include IVIG, Cipro or Levaquin, Cidofovir or Leflunomide – consult ID
- g. Other IS options:
Switch from MPA to mTOR inhibitor
Switch from MPA to leflunomide

3. RE-TRANSPLANTATION

- a. Patients with graft loss due to BKN should be considered for re-transplantation
- b. Native or graft nephrectomy is not recommended
- c. Confirmation of viral clearance should be made prior to transplantation by plasma BK virus PCR

V. RESPONSIBILITY

Arundhati Kale, MD

VI. REVIEWED BY

Arundhati Kale, MD

Lavjay Butani, MD

Stephanie Nguyen, MD

Maha Haddad, MD

Gia Oh, MD

Machi Kaneko, MD

VII. REVIEWED DATE and REVIEW CYCLE: June 21, 2024

VIII. REFERENCES:

- a. BK Virus Nephropathy in Kidney Transplantation: A State-of-the-Art Review Sam Kant 1,2,* , Alana Dasgupta 3 , Serena Bagnasco 3 and Daniel C. Brennan 1,2; Viruses 2022, 14, 1616. <https://doi.org/10.3390/v14081616>
- b. BK polyomavirus in solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice; Hans H. Hirsch | Parmjeet S. Randhawa | on behalf of AST Infectious Diseases Community of Practice. Clinical Transplantation. 2019;33:e13528.

Medical Legal Disclaimer:

Welcome to the UC Davis Health, Department of Pediatrics, Clinical Practice Guidelines Website. All health and health-related information contained within the Site is intended chiefly for use as a resource by the Department's clinical staff and trainees in the course and scope of their approved functions/activities (although it may be accessible by others via the internet). This Site is not intended to be used as a substitute for the exercise of independent professional judgment. These clinical pathways are intended to be a guide for practitioners and may need to be adapted for each specific patient based on the practitioner's professional judgment, consideration of any unique circumstances, the needs of each patient and their family, and/or the availability of various resources at the health care institution where the patient is located. Efforts are made to ensure that the material within this Site is accurate and timely but is provided without warranty for quality or accuracy. The Regents of the University of California; University of California, Davis; University of California, Davis, Health nor any other contributing author is responsible for any errors or omissions in any information provided or the results obtained from the use of such information. Some pages within this Site, for the convenience of users, are linked to or may refer to websites not managed by UC Davis Health. UC Davis Health does not control or take responsibility for the content of these websites, and the views and opinions of the documents in this Site do not imply endorsement or credibility of the service, information or product offered through the linked sites by UC Davis Health. UC Davis Health provides limited personal permission to use the Site. This Site is limited in that you may not:

- Use, download or print material from this site for commercial use such as selling, creating course packets, or posting information on another website.
- Change or delete propriety notices from material downloaded or printed from it. · Post or transmit any unlawful, threatening, libelous, defamatory, obscene, scandalous, inflammatory, pornographic, or profane material, any propriety information belonging to others or any material that could be deemed as or encourage criminal activity, give rise to civil liability, or otherwise violate the law.
- Use the Site in a manner contrary to any applicable law.

You should assume that everything you see or read on this Site is copyrighted by University of California or others unless otherwise noted. You may download information from this Site as long as it is not used for commercial purposes, and you retain the proprietary notices. You may not use, modify, make multiple copies, or distribute or transmit the contents of this Site for public or commercial purposes without the express consent of UC Davis Health.